South Korea-based SK pharmteco and LOTTE BIOLOGICS have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market.
Through this collaboration, the two companies will jointly investigate providing integrated, one-stop contract development and manufacturing organisation (CDMO) services to global clients, offering differentiated ADC solutions that span from development to commercial manufacturing.
LOTTE BIOLOGICS will utilize its cGMP manufacturing capabilities and global quality competitiveness at its Syracuse Bio Campus in the US to deliver high-quality bioconjugation and drug substance manufacturing services.
Meanwhile, SK pharmteco will be responsible for linker–payload development and manufacturing within the chemical-synthesis portion of the process, complementing LOTTE BIOLOGICS’ bioconjugation and drug-substance manufacturing.
By combining technical expertise and global networks, the companies aim to create a fully integrated CDMO platform that minimizes development-to-manufacturing gaps, offers customized solutions for clients, and strengthens competitiveness in the rapidly expanding ADC sector.
They also plan to jointly pursue global marketing and client engagement to expand their customer base across key markets.
The partnership also aligns with the ongoing global trend toward supply chain reshoring, as each company possesses advanced manufacturing infrastructures in both the US and Europe.
